SCHEMBL9609534

SCHEMBL9609534

CC(=O)C(C)=Cc1ccc(C(C)(C)C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.53
TRPV1 Q8NER1 2/20 0.48
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 2/20 0.44
MAPT P10636 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
AKR1C3 P42330 1/20 0.44
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
HDAC1 Q13547 1/20 0.42
HTT P42858 1/20 0.42
HIF1A Q16665 1/20 0.42
ESRRG P62508 4/20 0.41
LMNA P02545 1/20 0.41
TYR P14679 1/20 0.41
SRD5A2 P31213 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2005650 0.86 AKR1C3 (0.62) CYP1A2TRPV1ALDH1A1MEN1KMT2A
SCHEMBL2005648 0.86 AKR1C3 (0.62) CYP1A2TRPV1ALDH1A1MEN1KMT2A
SCHEMBL28961064 0.85 AKR1C3 (0.60) CYP1A2TRPV1ALDH1A1MEN1KMT2A
SCHEMBL28915265 0.83 CYP1A2 (0.49) CYP1A2TRPV1ALDH1A1MEN1KMT2A
SCHEMBL30103348 0.83 CYP1A2 (0.49) CYP1A2TRPV1ALDH1A1MEN1KMT2A
SCHEMBL4797439 0.82 AKR1C3 (0.56) CYP1A2TRPV1ALDH1A1MEN1KMT2A
SCHEMBL28915270 0.82 CYP1A2 (0.47) CYP1A2TRPV1ALDH1A1MEN1KMT2A
SCHEMBL30103347 0.82 CYP1A2 (0.47) CYP1A2TRPV1ALDH1A1MEN1KMT2A
SCHEMBL9637976 0.79 CYP1A2 (0.50) CYP1A2TRPV1ALDH1A1MEN1KMT2A
SCHEMBL1999710 0.78 MAPT (0.53) CYP1A2TRPV1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000192-B2 Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same TAKASAGO INTERNATIONAL CORPORATION (JP) 2015-04-07 US disclosed
US-9000192-B2 Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same TAKASAGO INTERNATIONAL CORPORATION (JP) 2015-04-07 US disclosed
US-8674144-B2 Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same TAKASAGO INTERNATIONAL CORPORATION (JP) 2014-03-18 US disclosed
US-8674144-B2 Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same TAKASAGO INTERNATIONAL CORPORATION (JP) 2014-03-18 US disclosed
US-20130217895-A1 CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-08-22 US disclosed
US-20130217895-A1 CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-08-22 US disclosed
EP-2543437-A2 HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST Takasago International Corporation (JP) 2013-01-09 EP disclosed
WO-2012074128-A1 CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-06-07 WO disclosed
US-20120136176-A1 CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-05-31 US disclosed
US-20120136176-A1 CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-05-31 US disclosed
WO-2011108672-A2 HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST 高砂香料工業株式会社 (JP) 2011-09-09 WO disclosed
US-4241058-A INSECTICIDES, MITICIDES, SYSTEMIC HOFFMANN-LA ROCHE INC. (US) 1980-12-23 US disclosed
EP-0005541-A2 Substituted piperidine, morpholine or piperidone derivatives, fungicides containing these compounds, process for their preparation and their use, and the use of these compounds as fungicides F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1979-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136176-A1 CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME HMOX1, HIRA, HRH1 CYP1A2 2014/4885TRPV1 603/4885ALDH1A1 122/4885
US-20130217895-A1 CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME HMOX1, NQO1, CBR3 CYP1A2 694/4885TRPV1 862/4885ALDH1A1 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.